4-[6-(2,7-diazaspiro[4.4]nonan-2-yl)-3-pyridinyl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
C24H24N8 — CID 126740161
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[6-(2,7-diazaspiro[4.4]nonan-2-yl)-3-pyridinyl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
4-[6-(2,7-diazaspiro[4.4]nonan-2-yl)-3-pyridinyl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (PubChem CID 126740161) has the molecular formula C24H24N8 and a molecular weight of 424.51 g/mol. Its IUPAC name is 4-[6-(2,7-diazaspiro[4.4]nonan-2-yl)-3-pyridinyl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile.
Molecular Properties
| Compound Name | 4-[6-(2,7-diazaspiro[4.4]nonan-2-yl)-3-pyridinyl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
|---|---|
| PubChem CID | 126740161 |
| Molecular Formula | C24H24N8 |
| Molecular Weight | 424.51 g/mol |
| Exact Mass | 424.21 |
| IUPAC Name | 4-[6-(2,7-diazaspiro[4.4]nonan-2-yl)-3-pyridinyl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
| SMILES | Cn1cc(-c2cc(-c3ccc(N4CCC5(CCNC5)C4)nc3)c3c(C#N)cnn3c2)cn1 |
| InChI | InChI=1S/C24H24N8/c1-30-13-20(12-28-30)18-8-21(23-19(9-25)11-29-32(23)14-18)17-2-3-22(27-10-17)31-7-5-24(16-31)4-6-26-15-24/h2-3,8,10-14,26H,4-7,15-16H2,1H3 |
| InChIKey | DKXPOHIHJHYGQF-UHFFFAOYSA-N |
| XLogP | 2.86 |
| TPSA | 87.07 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 424.51 |
| LogP ≤ 5 | 2.86 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 126740161 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.